系统性红斑狼疮患者医疗质量:来自ACR RISE登记处的数据
该研究利用美国风湿病学会RISE登记处2017-2018年数据,纳入186家实践中27,567例SLE患者,评估5项质量指标的实践水平表现。结果显示肾脏筛查率仅39.5%,17.7%患者高血压未治疗,71.5%接受羟氯喹但仅62%剂量≤5.0 mg/kg/天,18.5%使用至少中等剂量激素≥90天,所有指标均存在显著实践差异。
要点
- SLE患者肾脏疾病筛查率低,仅39.5%接受充分筛查。
- 71.5%患者接受羟氯喹,但仅62%剂量≤5.0 mg/kg/天。
- 18.5%患者使用至少中等剂量糖皮质激素≥90天。
核心结论
- 美国SLE患者医疗存在潜在差距,实践差异显著,开发针对SLE重要医疗过程的质量指标可能改善医疗质量。
研究设计与样本
- 基于美国风湿病学会RISE登记处的数据,纳入2017-2018年至少两次间隔≥30天有SLE代码就诊的患者,计算5项质量指标的实践水平表现,并使用逻辑回归评估独立预测因素。
主要发现
- 共纳入来自186家实践的27,567例独特患者,91.7%为女性,48%为白人,平均年龄53.5±15.2岁。
- 仅39.5%患者接受充分的肾脏表现筛查。
- 血压评估常见(94.4%),但17.7%患者高血压未治疗。
- 71.5%患者接受羟氯喹,但仅62%剂量≤5.0 mg/kg/天。
- 18.5%患者使用至少中等剂量激素≥90天,所有指标均存在显著实践差异。
关键数值与推荐
- 肾脏疾病筛查率39.5%。
- 血压评估率94.4%,未治疗高血压比例17.7%。
- 羟氯喹处方率71.5%,剂量≤5.0 mg/kg/天比例62%。
- 至少中等剂量激素使用≥90天比例18.5%。
临床怎么用
- 临床应关注SLE患者肾脏筛查、血压管理、羟氯喹安全剂量及避免长期中等剂量激素使用。
局限性
- 部分表现差异可能由疾病严重程度差异解释,但显著差异提示质量指标开发的重要性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although multiple national quality measures focus on the management and safety of rheumatoid arthritis, few measures address the care of patients with systemic lupus erythematosus (SLE). Our objective was to apply a group of quality measures relevant to the care of patients with SLE, and we used the American College of Rheumatology's Rheumatology Informatics System for Effectiveness (RISE) registry to assess nationwide variations in care. METHODS: The data derived from RISE and included patients who had ≥2 visits with SLE codes ≥30 days apart in 2017-2018. We calculated performance on 5 quality measures: renal disease screening, blood pressure assessment and management, hydroxychloroquine (HCQ) prescribing, safe dosing for HCQ, and prolonged glucocorticoid use at doses of >7.5 mg/day. We reported performance on these measures at the practice level. We used logistic regression to assess independent predictors of performance after adjusting for sociodemographic and utilization factors. RESULTS: We included 27,567 unique patients from 186 practices; 91.7% were female and 48% White, with a mean age of 53.5 ± 15.2 years. Few patients had adequate screening for the development of renal manifestations (39.5%). Although blood pressure assessment was common (94.4%), a meaningful fraction of patients had untreated hypertension (17.7%). Many received HCQ (71.5%), but only 62% at doses of ≤5.0 mg/kg/day. Some received at least moderate-dose steroids for ≥90 days (18.5%). We observed significant practice variation on every measure. CONCLUSION: We found potential gaps in care for patients with SLE across the US. Although some performance variation may be explained by differences in disease severity, dramatic differences suggest that developing quality measures to address important health care processes in SLE may improve care.
引用
- Schmajuk G, Li J, Evans M, et al. Quality of Care for Patients With Systemic Lupus Erythematosus: Data From the American College of Rheumatology RISE Registry. Arthritis Care Res (Hoboken). 2021. PMID: 32937019. doi:10.1002/acr.24446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。